TruScreen Appoints New Director

NZX and Media Release 21 December, 2017
NZX Limited
WELLINGTON

TruScreen Appoints New Director
Cervical cancer screening technology company, TruScreen Limited (NZAX: TRU) is pleased to
announce the appointment of Mr John (Chris) Lawrence as a director to the TruScreen Board,
effective from 21 December 2017.
Chris is a successful New Zealand businessman and a significant investor in life science and bio
technology businesses. He is a significant investor in Truscreen and was a major contributor to the
March 2017 capital raising.
Chairman of TruScreen, Mr Robert Hunter, commented: “We are fortunate to have Mr Lawrence join
the Board. His business experience and alignment with shareholder and company objectives will be
of value as we progress our commercial strategy.”
Mr Lawrence is ordinarily resident in New Zealand and has been appointed by the current TruScreen
directors, as permitted under TruScreen’s constitution. He will hold office until TruScreen’s 2018
Annual Meeting at which time he will offer himself for election by shareholders.
ENDS
For more information visit www.truscreen.com or contact:
Martin Dillon
TruScreen Chief Executive Officer
Email: martindillon@truscreen.com
Media Liaison
Jackie Ellis
Email: jackie@ellisandco.co.nz
Phone: +64 27 246 2505

About TruScreen:
TruScreen’s real time cervical cancer technology
utilises a digital wand which is placed on the
surface of the cervix to measure electrical and
optical signals from the surrounding tissue. A
sophisticated proprietary algorithm framework
distinguishes between normal and abnormal
(cancerous and precancerous) tissue to identify
precancerous change, or cervical intraepithelial

neoplasia (CIN). A Single Use Sensor (SUS) is used for each patient to protect against cross-infection.